- Home
- AUPH vs MDXG Comparison
AUPH vs MDXG Comparison
Compare AUPH & MDXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUPH
- MDXG
- Stock Information
- Founded
- AUPH 1993
- MDXG 2006
- Country
- AUPH Canada
- MDXG United States
- Employees
- AUPH N/A
- MDXG N/A
- Industry
- AUPH Biotechnology: Pharmaceutical Preparations
- MDXG Biotechnology: Pharmaceutical Preparations
- Sector
- AUPH Health Care
- MDXG Health Care
- Exchange
- AUPH Nasdaq
- MDXG Nasdaq
- Market Cap
- AUPH 1.1B
- MDXG 1.2B
- IPO Year
- AUPH 1999
- MDXG N/A
- Fundamental
- Price
- AUPH $8.13
- MDXG $7.95
- Analyst Decision
- AUPH Strong Buy
- MDXG Strong Buy
- Analyst Count
- AUPH 2
- MDXG 3
- Target Price
- AUPH $11.50
- MDXG $12.00
- AVG Volume (30 Days)
- AUPH 1.7M
- MDXG 607.5K
- Earning Date
- AUPH 05-01-2025
- MDXG 04-29-2025
- Dividend Yield
- AUPH N/A
- MDXG N/A
- EPS Growth
- AUPH N/A
- MDXG N/A
- EPS
- AUPH 0.04
- MDXG 0.28
- Revenue
- AUPH $235,133,000.00
- MDXG $348,879,000.00
- Revenue This Year
- AUPH $13.80
- MDXG $10.09
- Revenue Next Year
- AUPH $24.57
- MDXG $11.77
- P/E Ratio
- AUPH $203.13
- MDXG $29.00
- Revenue Growth
- AUPH 33.97
- MDXG 8.52
- 52 Week Low
- AUPH $4.71
- MDXG $5.47
- 52 Week High
- AUPH $10.67
- MDXG $10.14
- Technical
- Relative Strength Index (RSI)
- AUPH 51.32
- MDXG 45.17
- Support Level
- AUPH $7.92
- MDXG $7.72
- Resistance Level
- AUPH $8.85
- MDXG $8.15
- Average True Range (ATR)
- AUPH 0.42
- MDXG 0.31
- MACD
- AUPH 0.04
- MDXG 0.02
- Stochastic Oscillator
- AUPH 69.72
- MDXG 62.96
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing LUPKYNIS (voclosporin), an investigational drug, for the treatment of lupus nephritis (LN), and others. Geographically, it derives maximum revenue from the United States.
About MDXG MiMedx Group Inc
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are primarily targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.